DON'T CLOUD THE SUN-SAFE MESSAGE
8 December 2018
Mark Whittaker’s ‘Here comes the sun; Defending our summer rays’ (GW 24 Nov) clouds the sun-safe message – which could have disastrous consequences. The scientific evidence is clear and undisputable that UV exposure and the damage it causes is the single greatest risk factor for developing melanoma. UV radiation damages skin cells and causes mutations in DNA. And melanoma kills. It is the most common cancer affecting 15 to 39 year old Australians, and kills one Australian every five hours.
Sunshine isn’t the culprit here, but excess sunshine is. We enjoy our iconic Aussie outdoor lifestyle as much as the next person. But with one of the highest melanoma rates in the world, all Australians, including Good Weekend writers and editors, have a responsibility to advocate for enjoying sunshine safely. Living a sun-safe life is as simple as wearing a broad-brimmed hat, using 50+ sunscreen, covering up with long pants, sleeves and sunglasses, and seeking shade in the hottest part of the day.
By alluding to the many possible therapeutic benefits of sunshine while at the same time questioning whether his sunscreen use is ‘doing any good’, Mark Whittaker is doing all Australians a disservice. His reference to a small 1998 German study about possible therapeutic benefits of tanning beds is also dangerous. How many of those 18 participants went on to develop melanoma from their sunbed use? Melanoma Institute Australia led the campaign to have commercial sunbeds banned across the country due to their high melanoma risk, with many states in the USA following suit andthe UK now lobbying for a similar ban.
Mark also uses the anomaly of why some people develop melanoma but others don’t, to question how sun exposure can be to blame. The answer lies in genetics – and not in undermining the dangerous impact of UV exposure. Our researchers have discovered many of the hereditary genes that explain why some people get melanoma and others do not. A simple glance at the DNA of skin melanomas shows that nearly all have been caused by sun damage.
Sunshine may well have many therapeutic benefits, but questioning long-held and scientifically proven evidence about sunscreen and the link between UV exposure and melanoma is dangerous. And the cusp of summer, when UV levels are at their highest and most damaging, is not the time to be playing Devil’s Advocate.
While we at Melanoma Institute Australia are investing in research and trialling new melanoma treatments, as well as educating the community about the need to protect themselves from the sun, it is frustrating and disheartening to see Good Weekend clouding the issue about sun exposure and potentially undermining our efforts to save lives.
Just as we will continue to fight to save the lives of melanoma patients, many in their teens, 20s and 30s, we will continue to espouse the danger of excessive sun exposure and advocate for living a sun-safe life.
And Mark, please use that Sun Smart app. It just may save your life.
Professor Georgina Long and Professor Richard Scolyer
Melanoma Institute Australia
For more information, please contact:
Jennifer Durante |Melanoma Institute Australia | 0412 798 990 |firstname.lastname@example.org
"International collaboration remains the key to ensuring this pioneering research continues so we can increase survival rates for advanced melanoma patients and move us closer to achieving our goal of zero deaths from melanoma," says Professor Georgina Long, of the clinical trial results presented at ESMO 2018.
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.
A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.
The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.
The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
When David lost his life last year, he was 33, with three daughters under six.
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.